Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way
Saturday, January 29, 2022
1:30 PM – 2:30 PM ET
Sponsored By
Description
How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant
EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?
This PeerView Live Candid Conversations & Clinical Consults will answer these and other burning questions. Experts in thoracic surgery and medical oncology will come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they will provide direction on how to determine which patients are appropriate candidates for adjuvant EGFRtargeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC.
Agenda
Welcome, Introduction, and Goal-Setting
Candid Conversations
• Need-to-Know Updates on the Practice-Changing Role of EGFR-Targeted Therapy in Earlier Stages of Lung Cancer: Latest Evidence, Opportunities to Improve Outcomes, Critical Questions, and Implications for Surgeons
Clinical Consults and Multidisciplinary Care Best Practices
• Integrating EGFR-Targeted Therapy Into Multimodal Treatment of Patients With Early-Stage Lung Cancer
Summary, Reflections, and Take-Home Points
This CME activity is provided by Medical Learning Institute, Inc.
This activity is developed with our educational partner, PVI, Peerview Institute for Medical Education.
This activity is supported by an independent educational grant from AstraZeneca.